Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 21.05.2019 | 16:47

Aladdin Healthcare Technologies SE: Signs partnership agreement with the Norweigan Centre of Healthy Ageing (NO-Age)

DGAP-Media / 21.05.2019 / 16:47

Aladdin Healthcare Technologies SE
signs a partnership agreement with the Norweigan Centre of Healthy Ageing (NO-Age)
(BERLIN, Germany and LONDON, England) 21 May 2019 - Aladdin Healthcare Technologies SE ("Aladdin"), a cutting-edge technology leader developing AI for innovative healthcare solutions that will ensure every dollar in healthcare is spent more efficiently, today announced the signing of a partnership with the Norweigan Centre of Healthy Ageing (NO-Age). NO-Age and Aladdin have agreed to collaborate, innovate and transform the future of digital healthcare, bringing positive health outcomes to people who have ageing related chronic diseases, such as Alzheimer's disease (AD), cardiovascular diseases, and diabetes. The parties intend to focus on the following 3 specific areas, which will enable the development of a superior AI diagnosis toolkit for early disease detection, clinical trials and Research and Development for key compounds, with a view to new drug and treatment discovery.

*To develop mitophagy-target Alzheimer's disease​ biomarkers study with AI assistance.
*To develop a machine learning platform for the detection and analyse of NAD+, to speed up the clinical trial and drug discovery process.
*To develop a screening and early diagnostic tool for Alzheimer's disease​ using AI with tabular data, retina images, brain CT and MRI images, quizzes and IoT recorded walking path data.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, commented: "We are delighted to be entering into this partnership and look forward to combining Aladdin's technological expertise with NO-Age's medical experience, in an attempt to confront Alzheimer's disease. The World Health Organization believes Alzheimer's will be a Global Epidemic by 2050 so action against it needs to be taken imminently."

The partnership brings together a combination of world-class doctors, scientists, AI engineers from leading medical and research institutes. Both parties view the partnership as a fundamental forward step to achieve the end goal of accelerating medical research and transforming patient care.

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a cutting-edge technology company leveraging blockchain, artificial intelligence and machine-learning techniques to ensure every dollar in healthcare is spent more efficiently. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to ethically and securely gather large sets of health and lifestyle data. These datasets are then analysed and used to reduce costs and improve the efficiency of healthcare treatments. Aladdin's analysis can identify trends related to chronic diseases, thus empowering patients by providing insight into the various elements affecting their health, while improving outcomes and overall access to healthcare. Aladdin's vision is to move toward an era of more efficient healthcare management and realise their purpose of improving global health outcomes.

About Norwegian Centre on Healthy Ageing (NO-Age)
Norwegian Centre on Healthy Ageing (NO-Age), a virtual Norwegian integrated, interdisciplinary, international centre for human ageing research, with a translational goal to empower people to live longer, healthier, and more meaningful lives (Official website: NO-Age is anchored on Ahus. The current No-Age Centre network consists of members and research groups from world-leading universities (Europe: U of Oslo, Cambridge, Oxford, ULC, U of Copenhagen; U.S: Harvard University, U of Washington, National Institutes of Health (NIA-NIH), Stanford, Princeton, Buck Institute for Research on Aging; Asia: University of Hong Kong, Sun Yat-sen University). NO-Age aims to employ a common conceptual framework to understand the complex interplay of biological, physiological, cultural, and social factors that influence health and wellbeing at both the individual and population levels. NO-Age actively engages with our stakeholders to develop interventional strategies and policies to promote healthy living and social participation at old age. The maintenance of a healthy ageing brain is currently a primary goal of NO-Age. With a combinational approach of cross-species laboratory experiments, artificial intelligence (AI), and clinical patient samples, NO-Age aims to focus on the most common dementia, Alzheimer's disease (AD), covering all the major aspects of AD research including novel etiologies, early biomarker development, drug screening, and clinical trials. The final aim of NO-Age is to have Norway as an international research and development hub on normal ageing, and the age-predisposed AD.  


End of Media Release

Issuer: Aladdin Healthcare Technologies SE
Key word(s): Information technology

21.05.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this


UniDevice AG: Fortsetzung des Wachstumskurses erwartet

Im ersten Halbjahr 2020 verzeichnete die UniDevice AG ein deutliches Umsatz- (+5,9 %) und überproportionales EBIT-Wachstum (+38,6 %). Der Broker für Kommunikations- und Unterhaltungselektronik mit Schwerpunkt auf hochpreisige Smartphones erwartet für das Gesamtjahr die Fortsetzung des eingeschlagenen Wachstumskurses und weiterhin eine spürbare Verbesserung des Rentabilitätsniveaus. Bei einem von uns ermittelten Kursziel von 3,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Delivery Hero verstärkt seine globale Präsenz und erwirbt Glovos Geschäft in Lateinamerika

16. September 2020, 17:45

Aktuelle Research-Studie

Coreo AG

Original-Research: Coreo AG (von GBC AG): Kaufen

18. September 2020